Rani Therapeutics Joins FDA Emerging Technology Platform

Rani Therapeutics Holdings, Inc. (Nasdaq: RANI) has announced that its RaniPill® Capsule platform technology has been accepted into the FDA's Emerging Technology Program (ETP). This acceptance marks a significant step for the clinical-stage biotherapeutics company, which specializes in the oral delivery of biologics.